Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding
This study has been completed.
Sponsor:
Luitpold Pharmaceuticals
Information provided by:
Luitpold Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00395993
First received: November 2, 2006
Last updated: October 14, 2008
Last verified: October 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Estimated Study Completion Date: | April 2006 |
| Estimated Primary Completion Date: | No date given |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Gordon S, Hadley PE, Van Wyck DB, Mangione A. Ferric Carboxymaltose, a New IV Iron Agent for Iron Deficiency Anemia in Heavy Uterine Bleeding. Society for the Advancement of Blood Management 6th Annual Meeting 2007.
Gordon S, Hadley PE, Van Wyck DB, Mangione A. Iron Carboxymaltose, a New Intravenous Iron Agent for Iron Deficiency Anemia in Heavy Uterine Bleeding. American College of Obstetricians & Gynecologists: 108S 2007.
Morrison J, Patel S, Watson W, Zaidi QR, Mangione A, Goss TF. Assessment of the Prevalence and Impact of Anemia on Women Hospitalized for Gynecologic Conditions Asscoiated with Heavy Uterine Bleeding. The Journal of Reproductive Medicine: May;53(5):323-30 2008.
James AH, Patel ST, Watson W, Zaidi QR, Mangione A, Goss TF. An Assessment of Medical Resource Utilization and Hospitalization Cost Associated with a Diagnosis of Anemia in Women with Obstetrical Bleeding in the United States. Journal of Women's Health 2008; Volume 17: 1279-1284.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):